Significant OS Benefit with Glofitamab plus GemOx in Transplant-Ineligible Patients with Relapsed or Refractory DLBCL By Ogkologos - December 6, 2024 711 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the STARGLO study Source RELATED ARTICLESMORE FROM AUTHOR Antitumour Activity of Rezatapopt Provides Proof of Concept for p53 Reactivation in Patients with TP53 Y220C-mutated Solid Tumours Rare Disease Day 2026: Advancing equity for people living with rare cancers in Europe EMA Recommends Extension of Therapeutic Indications for Ponatinib MOST POPULAR Six Months Immunogenicity of COVID-19 mRNA-based Vaccine in Patients with Actively... December 14, 2021 Enhertu Improves Survival for Metastatic “HER2-Low” Breast Cancer July 5, 2022 Why People With Cancer Need to Be Taking Care of Their... August 27, 2020 A new target to slow down ageing and reduce blood cancer... June 29, 2023 Load more HOT NEWS Phytochemicals and Antioxidants First Direct Comparison of Ibrutinib versus Acalabrutinib in Patients with Previously... KRASG12 Mutations Are Biomarkers for Reduced Overall Survival Benefit of Treatment... What to Know About Cancer Clinical Trial Matching Programs
